
Psychotherapy-based interventions for non-alcohol substance use disorders (SUDs) have been evaluated across different populations and outcome domains. This review synthesized randomized evidence published between 2022 and 2025 and assessed its risk of bias and certainty. The review followed PRISMA 2020 and was registered in PROSPERO (CRD420261304767). PubMed, PsycINFO, Web of Science, and Scopus were searched for studies published between January 2022 and December 2025. Eligible studies were primary reports of efficacy-focused randomized controlled trials involving participants with diagnosed non-alcohol SUDs and reporting at least one actual substance-use outcome. Alcohol-only studies, pilot/feasibility trials, secondary analyses, and mechanism-focused reports were excluded. Risk of bias was assessed using RoB 2 and certainty using GRADE. Findings were synthesized narratively. Eligibility criteria were narrowed during peer review. Four trials evaluated integrated motivational interviewing and cognitive behavioral therapy (CBT), cannabis-focused CBT, acceptance and commitment therapy combined with contingency management, and a brief family intervention. Between-group substance-use findings favored the interventions in two trials, were inconclusive in one, and showed no significant difference in another. Psychological, functional, and treatment-engagement findings were mixed. Two assessed substance-use results were judged at high risk of bias, and two raised some concerns. Certainty was low for two substance-use comparisons and very low for two, reflecting risk of bias and imprecision. The four heterogeneous trials provided mixed evidence on substance-use and psychosocial outcomes. Low to very low certainty precludes conclusions about which interventions or recovery domains benefit most. Larger trials with prespecified analyses and sustained follow-up are needed.
Background This study addresses a gap in literature by examining associations between criminal justice system contact (i.e., arrest, probation, parole) and prescription opioid misuse motives and sources among adolescents and young adults.Methods Data from the National Survey on Drug Use and Health (2015-2019) were analyzed. Respondents reporting past-year prescription opioid misuse completed follow-up questions on motives (e.g., pain relief, relaxation/sleep, recreational) and sources (e.g., doctor, free from friend/relative, purchased, theft). Motives and sources were modeled as a function of criminal justice system contact and relevant covariates, separately by age group.Results Multinomial logistic regression revealed significant differences by criminal justice contact. Both adolescents and young adults with criminal justice system contact were more likely to report recreational or sleep/relaxation motives compared to pain relief. Among young adults, criminal justice system contact was associated with greater likelihood of obtaining opioids for free, through purchase, or by theft rather than from a doctor.Conclusions The elevated likelihood of endorsing riskier motives and sources identifies adolescents and young adults with criminal justice system contact as a high-need population for targeted substance use programming. A multidimensional framework addressing the intersection of crime and health is essential to reducing disparities and criminal involvement.
Modafinil is a stimulant drug that is primarily prescribed for the management of the sleep disorder narcolepsy. Approximately 10% of UK university students use it as a cognitive enhancer (CE) to help with their studies, but there has been limited research aimed at trying to understand this statistic. We surveyed students who are using modafinil as a cognitive enhancer, with the aim of understanding the detailed patterns of modafinil use. Students were using modafinil as a cognitive enhancer in the mistaken belief that it was illegal to do so, but unconcerned by that legal status or the side effects they experienced, believing that it is effective as a cognitive enhancer. Average length of modafinil use was 11 months, obtained from online pharmacies and with modest doses taken. Modafinil use was planned and strategic, aimed at improving focus and concentration with limited appetite for any sort of intervention by the student’s university. However some expressed concern about addiction and dependence, and there was concern about long-term effects. UK university students are using modafinil as a cognitive enhancer in a stable and planned but unregulated way.